N-substituted Indole Derivatives for EP2 Receptor Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for various diseases, including cancers and inflammatory conditions, face limitations due to the overexpression of PGE2 and its receptors EP2 and EP4, which contribute to tumor growth, immune evasion, and inflammation, with COX2 inhibitors showing cardiovascular side effects and limited efficacy in certain cases.
Innovation Solution
Development of novel N-substituted indole derivatives that act as modulators of the PGE2 receptor EP2, potentially used alone or in combination with EP4 modulators, to block EP2 and/or EP4 receptors, thereby inhibiting tumor growth, immune suppression, and inflammation, while minimizing cardiovascular risks.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If COX2 inhibitors are used to treat cancers and inflammatory conditions, then tumor growth and inflammation are inhibited, but cardiovascular side effects occur
Solution Approach 1:
The patent segments the non-selective COX inhibition into selective EP2 and EP4 receptor inhibition. Instead of blocking COX2 enzyme activity broadly (which affects both protective and harmful prostaglandin pathways), the invention uses selective EP2/EP4 antagonists to target only the receptors mediating tumor growth and inflammation, sparing cardiovascular protective pathways.
Solution Approach 2:
The invention applies local quality by creating receptors with specific binding properties. The EP2 and EP4 receptors are targeted with high specificity using structurally selective antagonists, allowing differential inhibition of prostaglandin effects in different tissues - anti-tumor and anti-inflammatory in target tissues while preserving cardiovascular homeostasis.
2Reliability
If COX2 inhibitors are used to block PGE2 production, then tumor growth is inhibited, but efficacy is limited in certain cancer types
Solution Approach 1:
The patent creates EP2 and EP4 antagonists with universal applicability across multiple cancer types. By targeting the downstream prostaglandin receptors rather than the upstream COX2 enzyme, the invention achieves broader efficacy across diverse cancers including colorectal, gastric, pancreatic, breast, ovarian, and other malignancies where PGE2-EP2/EP4 signaling is upregulated.
Solution Approach 2:
The invention changes the therapeutic parameter from enzyme inhibition (COX2) to receptor inhibition (EP2/EP4). This parameter shift allows the same therapeutic approach to be effective across different cancer types that share the common pathway of PGE2-EP2/EP4 mediated tumorigenesis, overcoming the limitations of COX2 inhibitor efficacy in certain cancers.
3Reliability
If PGE2 signaling is blocked to prevent immune evasion, then tumor growth is inhibited, but immune suppression mechanisms may be activated
Solution Approach 1:
The patent extracts the immune-modulatory function from the COX2-PGE2 pathway by selectively blocking EP2 and EP4 receptors. This extraction allows inhibition of PGE2-mediated immune suppression in the tumor microenvironment while potentially preserving other immune-protective prostaglandin pathways that act through different receptors.
Data Source
AI summary
The present invention relates to derivatives of formula (I)wherein R1, and R2 are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as modulators of the prostaglandin 2 receptor EP2.